Biotech Investing Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027
Biotech Investing Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027
Biotech Investing Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference
pharmaceutical investing Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
Biotech Investing Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders
Biotech Investing Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT
biotech investing Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis
Focus Graphite Receives Conditional Funding of up to $14.1M to Advance Canada's First Electrothermal Fluidized Purification Demonstration Plant
SAGA Metals Provides Update on Double Mer Uranium Project: A Well-Positioned Asset in North America as the Uranium Boom Accelerates
